Economic Evaluation and Decision Making: Reimbursing Trastuzumab in Early-Stage Breast Cancer

Author： Simoens Steven  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.3, 2007-01, pp. : 181-185

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab in Early-Stage Breast Cancer: The Question of Treatment Timing

By Simoens Steven  

PharmacoEconomics, Vol. 26, Iss. 10, 2008-01 ,pp. : 807-809

Adis International

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L.   Keam Susan J.  

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 449-475

Adis International

Access to resources Recommend Favorite

In defence of trastuzumab for early breast cancer

By  

Inpharma, Vol. 1, Iss. 1521, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Quality-of-Life Considerations in the Treatment of Early-Stage Breast Cancer in the Elderly

By Reimer Toralf   Gerber Bernd  

Drugs & Aging, Vol. 27, Iss. 10, 2010-10 ,pp. : 791-800

Adis International

Access to resources Recommend Favorite

G-CSF cost-neutral for early-stage breast cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 646, 2012-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite